| Blockade of the IL-1R1/TLR4 pathway mediates disease-modification therapeutic effects in a model of acquired epilepsy V Iori, AM Iyer, T Ravizza, L Beltrame, L Paracchini, S Marchini, M Cerovic, ... Neurobiology of disease 99, 12-23, 2017 | 175 | 2017 |
| Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models C Belgiovine, E Bello, M Liguori, I Craparotta, L Mannarino, L Paracchini, ... British journal of cancer 117 (5), 628-638, 2017 | 135 | 2017 |
| Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: A validation across two independent cohorts P Todeschini, E Salviato, L Paracchini, M Ferracin, M Petrillo, L Zanotti, ... Cancer Letters 388, 320-327, 2017 | 80 | 2017 |
| Protection of brain injury by amniotic mesenchymal stromal cell-secreted metabolites F Pischiutta, L Brunelli, P Romele, A Silini, E Sammali, L Paracchini, ... Critical care medicine 44 (11), e1118-e1131, 2016 | 78 | 2016 |
| MiRNA landscape in stage I epithelial ovarian cancer defines the histotype specificities E Calura, R Fruscio, L Paracchini, E Bignotti, A Ravaggi, P Martini, ... Clinical cancer research 19 (15), 4114-4123, 2013 | 78 | 2013 |
| Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective … M Petrillo, GF Zannoni, L Beltrame, E Martinelli, A DiFeo, L Paracchini, ... Annals of Oncology 27 (4), 625-634, 2016 | 72 | 2016 |
| lncRNAs as novel indicators of patients' prognosis in stage I epithelial ovarian cancer: A retrospective and multicentric study P Martini, L Paracchini, G Caratti, M Mello-Grand, R Fruscio, L Beltrame, ... Clinical Cancer Research 23 (9), 2356-2366, 2017 | 66 | 2017 |
| Antiangiogenic activity of trabectedin in myxoid liposarcoma: involvement of host TIMP‐1 and TIMP‐2 and tumor thrombospondin‐1 R Dossi, R Frapolli, S Di Giandomenico, L Paracchini, F Bozzi, S Brich, ... International Journal of Cancer 136 (3), 721-729, 2015 | 66 | 2015 |
| Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: a retrospective study L Beltrame, M Di Marino, R Fruscio, E Calura, B Chapman, L Clivio, ... Annals of Oncology 26 (7), 1363-1371, 2015 | 55 | 2015 |
| Genome-wide copy-number alterations in circulating tumor DNA as a novel biomarker for patients with high-grade serous ovarian cancer L Paracchini, L Beltrame, T Grassi, A Inglesi, R Fruscio, F Landoni, ... Clinical Cancer Research 27 (9), 2549-2559, 2021 | 34 | 2021 |
| Regional and temporal heterogeneity of epithelial ovarian cancer tumor biopsies: implications for therapeutic strategies L Paracchini, L Mannarino, I Craparotta, C Romualdi, R Fruscio, T Grassi, ... Oncotarget 12 (24), 2404, 2021 | 28 | 2021 |
| A prognostic regulatory pathway in stage I epithelial ovarian cancer: new hints for the poor prognosis assessment E Calura, L Paracchini, R Fruscio, A DiFeo, A Ravaggi, J Peronne, ... Annals of Oncology 27 (8), 1511-1519, 2016 | 24 | 2016 |
| Multisite analysis of high‐grade serous epithelial ovarian cancers identifies genomic regions of focal and recurrent copy number alteration in 3q26. 2 and 8q24. 3 S Ballabio, I Craparotta, L Paracchini, L Mannarino, S Corso, MG Pezzotta, ... International journal of cancer 145 (10), 2670-2681, 2019 | 23 | 2019 |
| Exome sequencing in an Italian family with Alzheimer’s disease points to a role for seizure-related gene 6 (SEZ6) rare variant R615H L Paracchini, L Beltrame, L Boeri, F Fusco, P Caffarra, S Marchini, ... Alzheimer's Research & Therapy 10, 1-20, 2018 | 17 | 2018 |
| Epithelioid pleural mesothelioma is characterized by tertiary lymphoid structures in long survivors: results from the MATCH study L Mannarino, L Paracchini, F Pezzuto, GE Olteanu, L Moracci, L Vedovelli, ... International Journal of Molecular Sciences 23 (10), 5786, 2022 | 12 | 2022 |
| Detection of TP53 clonal variants in Papanicolaou test samples collected up to 6 years prior to high-grade serous epithelial ovarian cancer diagnosis L Paracchini, C Pesenti, M Delle Marchette, L Beltrame, T Bianchi, ... JAMA Network Open 3 (7), e207566-e207566, 2020 | 12 | 2020 |
| Expression profiles of PRKG1, SDF2L1 and PPP1R12A are predictive and prognostic factors for therapy response and survival in high‐grade serous ovarian cancer G Benvenuto, P Todeschini, L Paracchini, E Calura, R Fruscio, C Romani, ... International Journal of Cancer 147 (2), 565-574, 2020 | 11 | 2020 |
| Transcriptional characterization of stage I epithelial ovarian cancer: a multicentric study E Calura, M Ciciani, A Sambugaro, L Paracchini, G Benvenuto, S Milite, ... Cells 8 (12), 1554, 2019 | 10 | 2019 |
| Liquid Biopsy in the Clinical Management of High-Grade Serous Epithelial Ovarian Cancer—Current Use and Future Opportunities L Paracchini, M D’Incalci, S Marchini Cancers 13 (10), 2386, 2021 | 9 | 2021 |
| A systems biology approach to investigate the mechanism of action of trabectedin in a model of myelomonocytic leukemia L Mannarino, L Paracchini, I Craparotta, M Romano, S Marchini, R Gatta, ... The Pharmacogenomics Journal 18 (1), 56-63, 2018 | 9 | 2018 |
